Pre-made Lampalizumab benchmark antibody ( Fab, anti-CFD therapeutic antibody, Anti-ADIPSIN/ADN/DF/PFD Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.
| Products Name (INN Index) | Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody |
|---|---|
| INN Name | Lampalizumab |
| Target | CFD |
| Format | Fab |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | 4d9q:HL:ED/4d9r:HL:ED |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Tanox,Genentech |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Dry age-related macular degeneration |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CFD |
| Package |
